+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America

Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America

Haemophilia 7(3): 235-241

The optimal treatment of patients with von Willebrand's disease (vWD) remains to be defined. Moreover, it has not been firmly established which, if any, commonly measured parameters of von Willebrand factor (vWF) protein in the plasma are useful in guiding treatment. To better understand what guidelines physicians follow in the management of vWD, we surveyed 194 North American physicians who are members of the Hemophilia Research Society. Ninety-nine per cent of responding physicians depend on factor VIII (FVIII):C, vWF:RCo activity and vWF:AG to diagnose vWD, while only 49% use the bleeding time. The minimal goals of treatment for patients undergoing major surgery/trauma or central nervous system haemorrhage were FVIII:C and vWF:RCo activity greater than 80% while levels of more than 50% for minor surgery and dental extractions were considered adequate. Treatment of vWD was based on the type of vWD with type 1 patients being treated most often with desmopressin acetate (DDAVP) alone, types 2A and 2B patients with a combination of DDAVP and a vWF-containing FVIII product, type 3 patients with vWF-containing concentrate. Viral infections, including human immunodeficiency virus, hepatitis A, B and C viruses, and parvovirus have been seen in vWD and the efficacy of viral attenuation processes is a major criterion for the selection of treatment by physicians. Based on this survey, prospective studies need to be designed to address the clinical efficacy, safety and predictive value of laboratory monitoring of patients with vWD.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 046616471

Download citation: RISBibTeXText

PMID: 11380626

DOI: 10.1046/j.1365-2516.2001.00498.x

Related references

Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 10(2): 158-161, 2004

Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres. Seminars in Thrombosis and Hemostasis 42(1): 36-41, 2016

Desmopressin Use in Type 2B von Willebrand Disease in North America, a Survey of Members of the Hemophilia Research Society of North America. Blood 100(11): Abstract No 2750, 2002

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 9(Suppl. 1): 19-26; Discussion 26, 2003

Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 18(1): 63-68, 2012

Current practice perspectives on the management of thrombosis in children with renal insufficiency: the results of a survey of pediatric hematologists in North America. Pediatric Blood and Cancer 51(5): 657-661, 2008

A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B. Australian Dental Journal 46(1): 37-40, 2001

Pallidotomy: a survey of current practice in North America. Neurosurgery 39(4): 883-90; Discussion 890-2, 1996

Practice patterns in haemophilia A therapy--a survey of treatment centres in the United States. Haemophilia 9(5): 549-554, 2003

A Survey of Clinical Practice Patterns in Management of Graves Disease in the Middle East and North Africa. Endocrine Practice 23(3): 299-308, 2017

High-Flow Nasal Cannulae (HFNC) in Neonates: A Survey of Current Practice in Level 1 Perinatal Centres in the German State of North Rhine-Westphalia. Zeitschrift für Geburtshilfe und Neonatologie 219(6): 253-258, 2016

Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 9(3): 292-297, 2003

Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A, haemophilia B and von Willebrand's disease. UK Regional Haemophilia Centre Directors Committee. Blood Coagulation & Fibrinolysis 3(2): 205-214, 1992

Survey of current practice related to grading of rejection in cardiac transplant recipients in North America. Cardiovascular Pathology 20(5): 261-265, 2012

Laboratory Testing, Diagnosis, and Management of von Willebrand Disease: Current Practice in Australasia. American Journal of Clinical Pathology 112(5): 712-719, 1999